Seckin Serin, Forman Eric J
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Columbia University Fertility Center, Columbia University Irving Medical Center, New York, New York, USA.
Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):216-223. doi: 10.1097/GCO.0000000000000865. Epub 2023 Mar 20.
Preimplantation genetic testing for the purpose of aneuploidy screening (PGT-A) has increased in use over the last decade.
Whether PGT-A benefits all of the patients that choose to employ it has been a concern, as recent studies have highlighted a potential decrease in cumulative live birth rate (CLBR) for younger patients undergoing embryo transfer. However, there are limitations to many of these studies and the intended benefit of PGT-A, which is to aid as a selection tool, thus increasing the live birth rate per transfer, must not be ignored.
PGT-A was never intended to increase CLBR. The purpose of PGT-A is to maximize the chance at live birth per transfer while minimizing the risk of clinical miscarriage, ongoing aneuploid pregnancy and futile transfers. However, if it harms CLBR in the process that has to be taken into consideration. This review will discuss PGT-A in terms of its benefits, risks, and how it has been shown to affect the cumulative live birth rate within in-vitro fertilization cycles.
在过去十年中，用于非整倍体筛查的植入前基因检测（PGT-A）的使用有所增加。
PGT-A是否对所有选择使用它的患者都有益一直是一个令人担忧的问题，因为最近的研究强调，接受胚胎移植的年轻患者的累积活产率（CLBR）可能会下降。然而，这些研究中的许多都存在局限性，并且PGT-A作为一种选择工具的预期益处，即提高每次移植的活产率，绝不能被忽视。
PGT-A的目的从来不是提高CLBR。PGT-A的目的是在将临床流产、持续非整倍体妊娠和无效移植的风险降至最低的同时，最大化每次移植的活产机会。然而，如果在此过程中它对CLBR产生了损害，这是必须要考虑的。本综述将从PGT-A的益处、风险以及它如何影响体外受精周期内的累积活产率等方面进行讨论。
